Press coverage about Exelixis (NASDAQ:EXEL) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.745832802839 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Form 4 EXELIXIS, INC. For: Jan 08 Filed by: Garber Alan M (streetinsider.com)
- Hot Stock’s Watch List – Exelixis, Inc. (NASDAQ: EXEL) – Alpha Beta Stock (alphabetastock.com)
- Exelixis – Looking Good For 2018 – Seeking Alpha (seekingalpha.com)
- 4 Reasons Exelixis, Inc. More Than Doubled in 2017 – Motley Fool (fool.com)
- Alan M. Garber Sells 15,000 Shares of Exelixis, Inc. (EXEL) Stock (americanbankingnews.com)
A number of equities analysts recently commented on EXEL shares. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Leerink Swann downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $34.00 to $28.00 in a research note on Friday, September 22nd. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Wednesday, October 18th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective for the company in a research note on Tuesday, January 2nd. Finally, Piper Jaffray Companies reissued an “overweight” rating on shares of Exelixis in a research note on Monday, October 16th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis presently has a consensus rating of “Buy” and an average price target of $32.13.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.18. The business had revenue of $152.50 million for the quarter, compared to the consensus estimate of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The business’s quarterly revenue was up 145.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.04) earnings per share. equities research analysts forecast that Exelixis will post 0.49 earnings per share for the current year.
In other news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the transaction, the director now directly owns 64,829 shares of the company’s stock, valued at $1,964,318.70. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.10% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.